# Argos Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/argos-therapeutics

- Industry: Biotechnology
- Headquarters: Durham, US
- Website: www.argostherapeutics.com
- Total disclosed funding: $137M
- Latest round: Series E (Aug 26, 2013)
- Investors on record: 24

## About

Founded in 1997, Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases.

## Funding rounds

- Series E, Aug 26, 2013, $43M — Aurora Capital Partners, Intersouth Partners, TVM Capital Life Science, CDPQ, Forbion, 5Y Capital, Green Cross Corporation, Pharmstandard International S.A., Lumira Ventures
- Series D, Sep 11, 2012, $14M — TVM Capital Life Science, Forbion, Lumira Ventures
- Series D, Apr 9, 2012, $9M — Aurora Funds, Intersouth Partners, TVM Capital Life Science, CDPQ, Forbion, 5Y Capital, Lumira Ventures
- Series C, Apr 23, 2008, $17M — Aurora Capital Partners, Intersouth Partners, TVM Capital Life Science, CDPQ, GeneChem, Forbion, 5Y Capital, DNX Ventures, Mizuho Capital, Kirin Pharma Company, Ltd., Capital Technologies, Lumira Ventures
- Series C, Mar 28, 2008, $13M — Aurora Funds
- Series B, Sep 10, 2001, $40M — Aurora Funds, Intersouth Partners, Pacific Horizon Ventures, TVM Capital Life Science, CDPQ, Houston Ventures, BD Ventures, Sutter Hill Ventures, GeneChem, Cordova Ventures, Senmed Medical Ventures, Oakwood Medical Investors, Harbinger Venture Capital, Vestcorp, Forbion, Lumira Ventures
- Series A, Jun 1, 2000, $1.6M — Aurora Funds

## Investors

- Aurora Funds (https://capitalatlas.ai/funds/aurora-funds) — Series A, Series B, Series C, Series D
- Intersouth Partners (https://capitalatlas.ai/funds/intersouth-partners) — Series B, Series C, Series D, Series E
- Pacific Horizon Ventures (https://capitalatlas.ai/funds/pacific-horizon-ventures) — Series B
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series B, Series C, Series D, Series E
- CDPQ — Series B, Series C, Series D, Series E
- Houston Ventures (https://capitalatlas.ai/funds/houston-ventures) — Series B
- BD Ventures (https://capitalatlas.ai/funds/bd-ventures) — Series B
- Sutter Hill Ventures (https://capitalatlas.ai/funds/sutter-hill-ventures) — Series B
- GeneChem (https://capitalatlas.ai/funds/genechem) — Series B, Series C
- Cordova Ventures (https://capitalatlas.ai/funds/cordova-ventures) — Series B
- Senmed Medical Ventures (https://capitalatlas.ai/funds/senmed-medical-ventures) — Series B
- Oakwood Medical Investors (https://capitalatlas.ai/funds/oakwood-medical-investors) — Series B
- Harbinger Venture Capital (https://capitalatlas.ai/funds/harbinger-venture-capital) — Series B
- Vestcorp (https://capitalatlas.ai/funds/vestcorp) — Series B
- Forbion (https://capitalatlas.ai/funds/forbion) — Series B, Series C, Series D, Series E
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Series B, Series C, Series D, Series E
- Aurora Capital Partners (https://capitalatlas.ai/funds/aurora-capital-partners) — Series C, Series E
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series C, Series D, Series E
- DNX Ventures (https://capitalatlas.ai/funds/dnx-ventures) — Series C
- Mizuho Capital (https://capitalatlas.ai/funds/mizuho-capital) — Series C
- Kirin Pharma Company, Ltd. — Series C
- Capital Technologies — Series C
- Green Cross Corporation — Series E
- Pharmstandard International S.A. — Series E